The comparison of nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS) with Ki67 proliferation marker expression in common skin tumors

Polish Journal of Pathology

Volumn 65, Issue 1, 2014, Pages 48-54

  Zduniak, Krzysztof ^a   Agrawal, Siddarth ^a   Symonowicz, Krzysztof ^a   Jurczyszyn, Kamil ^a   Ziółkowski, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Basal cell carcinoma; Keratoacanthoma; Ki67; NUCKS; Squamous cell carcinoma

Indexed keywords

KI 67 ANTIGEN; NUCKS PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; TUMOR MARKER;

ARTICLE; BASAL CELL CARCINOMA; CELL NUCLEUS; COMPARATIVE STUDY; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; HUMANS; KI-67 ANTIGEN; NUCLEAR PROTEINS; PHOSPHOPROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900531648     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2014.42669     Document Type: Article

References (32)

1. Grundt K, Haga IV, Aleporou-Marinou V, et al. Characterisation of the NUCKS gene on human chromosome 1q32.1 and the presence of a homologous gene in different species. Biochem Biophys Res Commun 2004; 323: 796-801.
2. Ostvold AC, Norum JH, Mathiesen S, et al. Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem 2001; 268: 2430-2440.
3. Wisniewski JR, Schwanbeck R. High mobility group I/Y: multifunctional chromosomal proteins causally involved in tumor progression and malignant transformation (review). Int J Mol Med 2000; 6: 409-419.
4. Sgarra R, Zammitti S, Lo Sardo A, et al. HMGA molecular network: from transcriptional regulation to chromatin remodeling. Biochim Biophys Acta 2010; 1799: 37-47.
5. Sgarra R, Rustighi A, Tessari MA, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004; 574: 1-8.
6. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14: 43764386.
7. Drosos Y, Kouloukoussa M, Østvold AC, et al. NUCKS overexpression in breast cancer. Cancer Cell Int 2009; 10: 19.
8. Grundt K, Skjeldal L, Anthonsen HW, et al. A putative DNA-binding domain in the NUCKS protein. Arch Biochem Biophys 2002; 407: 168-175.
9. Grundt K, Haga IV, Huitfeldt HS, Ostvold AC. Identification and characterization of two putative nuclear localization signals (NLS) in the DNA-binding protein NUCKS. Biochim Biophys Acta 2007; 1773: 1398-1406.
10. Wiśniewski JR, Zougman A, Krüger S, et al. Constitutive and dynamic phosphorylation and acetylation sites on NUCKS, ahypermodified nuclear protein, studied by quantitative proteomics. Proteins 2008; 73: 710-718.
11. Ziółkowski P, Gamian E, Osiecka B, et al. Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast. J Biomed Biotechnol 2009; 2009: 919645.
12. Sargent LM, Ensell MX, Ostvold AC, et al. Chromosomal changes in highand low-invasive mouse lung adenocarcinoma cell strains derived from early passage mouse lung adenocarcinoma cell strains. Toxicol Appl Pharmacol 2008; 233: 81-91.
13. Kikuchi A, Ishikawa T, Mogushi K, et al. Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis. Int J Cancer 2013; 132: 2295-2302.
14. Kuenen-Boumeester V, Van Der Kwast TH, Van Laarhoven HA, Henzen-Logmans SC. Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. J Clin Pathol 1991; 44: 208-210.
15. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322.
16. Mackiewicz-Wysocka M, Bowszyc-Dmochowska M, Strzelecka-Weklar D, et al. Basal cell carcinoma diagnosis. Contemp Oncol 2013; 17: 337-342.
17. Deo SV, Hazarika S, Shukla NK, et al. Surgical management of skin cancers: experience from aregional cancer centre in North India. Indian J Cancer 2005; 42: 145-150.
18. Lam L, Logan RM, Luke C, Rees GL. Retrospective study of survival and treatment pattern in acohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. Oral Oncol 2007; 43: 150-158.
19. Sánchez Yus E, Simón P, Requena L, et al. Solitary keratoacanthoma: aself-healing proliferation that frequently becomes malignant. Am J Dermatopathol 2000; 22: 305-310.
20. Connolly M, Narayan S, Oxley J, de Berker DA. Immunohistochemical staining for the differentiation of subungual keratoacanthoma from subungual squamous cell carcinoma. Clin Exp Dermatol 2008; 33: 625-628.
21. Pilloni L, Bianco P, Manieli C, et al. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas. Eur J Histochem 2009; 53: 113-116.
22. Sakiz D, Turkmenoglu TT, Kabukcuoglu F. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol Res Pract 2009; 205: 589-594.
23. Vidal CI, Goldberg M, Burstein DE, et al. p63 Immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors. Am J Dermatopathol 2010; 32: 257-261.
24. Chuang FH, Hsue SS, Wu CW, Chen YK. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma. J Oral Pathol Med 2009; 38: 753-758.
25. Bernardes VF, Gleber-Netto FO, Sousa SF, et al. Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: acase control study. J Exp Clin Cancer Res 2010; 29: 40.
26. Kimura S, Naganuma S, Susuki D, et al. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep 2010; 23: 1625-1633.
27. Tan KB, Lee YS. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology. Histopathology 2009; 55: 338-345.
28. Ishida M, Kushima R, Okabe H. Aberrant expression of class III β-tubulin in basal cell carcinoma of the skin. Oncol Rep 2009; 22: 733-737.
29. Sari Aslani F, Akbarzadeh-Jahromi M, Jowkar F. Value of CD10 expression in differentiating cutaneous basal from squamous cell carcinomas and basal cell carcinoma from trichoepithelioma. Iran J Med Sci 2013; 38: 100-106.
30. Wagoner J, Keehn C, Morgan MB. CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma. Am J Dermatopathol 2007; 29: 555-558.
31. Mantovani A. Cancer: inflaming metastasis. Nature 2009; 457: 36-37.
32. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as aconfounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010; 10: 2-3.